Tcr2 Therapeutics Financials
| TCRRDelisted Stock | USD 1.48 0.00 0.00% |
With this module, you can analyze Tcr2 financials for your investing period. You should be able to track the changes in Tcr2 Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Tcr2 |
Understanding current and past Tcr2 Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tcr2 Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Tcr2 Therapeutics' assets may result in an increase in income on the income statement.
The data published in Tcr2 Therapeutics' official financial statements usually reflect Tcr2 Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Tcr2 Therapeutics. For example, before you start analyzing numbers published by Tcr2 accountants, it's critical to develop an understanding of what Tcr2 Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Tcr2 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tcr2 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Tcr2 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Tcr2 Therapeutics. Please utilize our Beneish M Score to check the likelihood of Tcr2 Therapeutics' management manipulating its earnings.
Tcr2 Therapeutics Stock Summary
Tcr2 Therapeutics competes with Affimed NV, Pieris Pharmaceuticals, ADC Therapeutics, Agenus, and Revolution Medicines. TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor therapies for patients suffering from cancer. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Tcr2 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 105 people.| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US87808K1060 |
| Business Address | 100 Binney Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.tcr2.com |
| Phone | 617 949 5200 |
| Currency | USD - US Dollar |
You should never invest in Tcr2 Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Tcr2 Stock, because this is throwing your money away. Analyzing the key information contained in Tcr2 Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Tcr2 Therapeutics Key Financial Ratios
Generally speaking, Tcr2 Therapeutics' financial ratios allow both analysts and investors to convert raw data from Tcr2 Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Tcr2 Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Tcr2 Therapeutics reports annually and quarterly.Tcr2 Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tcr2 Therapeutics's current stock value. Our valuation model uses many indicators to compare Tcr2 Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tcr2 Therapeutics competition to find correlations between indicators driving Tcr2 Therapeutics's intrinsic value. More Info.Tcr2 Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Tcr2 Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Tcr2 Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tcr2 Therapeutics' earnings, one of the primary drivers of an investment's value.Tcr2 Therapeutics Market Pulse
| Quote | 1.48 |
| Change(%) | 0.00 |
| Change | 0.00 |
| Open | 1.48 |
| Low | 1.48 |
| High | 1.48 |
| Volume | 0 |
| Exchange | NASDAQ |
About Tcr2 Therapeutics Financials
What exactly are Tcr2 Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Tcr2 Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Tcr2 Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Tcr2 Therapeutics investors may use each financial statement separately, they are all related. The changes in Tcr2 Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Tcr2 Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Tcr2 Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Tcr2 Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Tcr2 has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Tcr2 Therapeutics' financials are consistent with your investment objective using the following steps:- Review Tcr2 Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Tcr2 Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Tcr2 Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Tcr2 Therapeutics' stock is overvalued or undervalued.
Tcr2 Therapeutics April 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tcr2 Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tcr2 Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tcr2 Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Tcr2 Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tcr2 Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.92 | |||
| Information Ratio | 0.0555 | |||
| Maximum Drawdown | 43.6 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.77 |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Tcr2 Stock
If you are still planning to invest in Tcr2 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tcr2 Therapeutics' history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |